Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.

Journal of medicinal chemistry 20150910

Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20150401

Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle.

Cell metabolism 20140603

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.

Nature reviews. Drug discovery 20140601

Identification of potent Yes1 kinase inhibitors using a library screening approach.

Bioorganic & medicinal chemistry letters 20130801

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

Cancer discovery 20130101

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

Cancer research 20121101

Olaparib, PARP1 inhibitor in ovarian cancer.

Expert opinion on investigational drugs 20121001

Clinical trials and future potential of targeted therapy for ovarian cancer.

International journal of clinical oncology 20121001

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.

EMBO molecular medicine 20121001

[Ovarian cancer-criteria of response and the timing of regimen change in chemotherapy for ovarian cancer].

Gan to kagaku ryoho. Cancer & chemotherapy 20121001

Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.

Current opinion in oncology 20120901

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.

Breast cancer research and treatment 20120901

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Cancer discovery 20120901

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.

Investigational new drugs 20120801

Neoadjuvant treatments for triple-negative breast cancer (TNBC).

Annals of oncology : official journal of the European Society for Medical Oncology 20120801

Olaparib in platinum-sensitive ovarian cancer.

The New England journal of medicine 20120712

Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option.

Breast cancer research and treatment 20120701

BAP1 loss defines a new class of renal cell carcinoma.

Nature genetics 20120701

Current and emerging targeted therapies for metastatic breast cancer.

Cancer 20120615

Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases.

Hepatology (Baltimore, Md.) 20120601

Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.

EMBO molecular medicine 20120601

A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120415

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

The New England journal of medicine 20120412

PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.

Cancer research 20120401

A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.

The oncologist 20120401

[PARP inhibitors and breast cancer: update and perspectives].

Bulletin du cancer 20120401

Drug candidates derailed in case of mistaken identity.

Nature 20120328

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120315

A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors.

Cancer science 20120301

Synthetic lethality of cohesins with PARPs and replication fork mediators.

PLoS genetics 20120301

Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents.

Neoplasia (New York, N.Y.) 20120301

Present status and problems on molecular targeted therapy of cancer.

Cancer research and treatment : official journal of Korean Cancer Association 20120301

Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors.

Nature biotechnology 20120219

Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair.

Molecular cell 20120210

Structural basis of selective inhibition of human tankyrases.

Journal of medicinal chemistry 20120209

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120201

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.

British journal of cancer 20120131

Basal breast cancer: a complex and deadly molecular subtype.

Current molecular medicine 20120101

Ovarian cancer: opportunity for targeted therapy.

Journal of oncology 20120101

BRCAness profile of sporadic ovarian cancer predicts disease recurrence.

PloS one 20120101

Molecular basis of triple negative breast cancer and implications for therapy.

International journal of breast cancer 20120101

Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer.

International journal of breast cancer 20120101

Therapeutic strategies in epithelial ovarian cancer.

Journal of experimental & clinical cancer research : CR 20120101

Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer.

PloS one 20120101

Major clinical research advances in gynecologic cancer in 2011.

Journal of gynecologic oncology 20120101

Advances in using PARP inhibitors to treat cancer.

BMC medicine 20120101

Novel binding mode of a potent and selective tankyrase inhibitor.

PloS one 20120101

Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.

Journal of oncology 20120101

Metastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the ATM gene.

PloS one 20120101

Brain metastases from endometrial carcinoma.

ISRN oncology 20120101

The combination of olaparib and camptothecin for effective radiosensitization.

Radiation oncology (London, England) 20120101

Combination drug delivery approaches in metastatic breast cancer.

Journal of drug delivery 20120101

Full-exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer.

PloS one 20120101

The first European interdisciplinary ewing sarcoma research summit.

Frontiers in oncology 20120101

Targeting the fanconi anemia pathway to identify tailored anticancer therapeutics.

Anemia 20120101

Inhibition of poly(ADP-ribose) polymerase interferes with Trypanosoma cruzi infection and proliferation of the parasite.

PloS one 20120101

Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.

Cell cycle (Georgetown, Tex.) 20111215

The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.

Current drug targets 20111201

Update on PARP1 inhibitors in ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology 20111201

PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.

Oncotarget 20111201

Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma.

Nuclear medicine communications 20111101

BRCA1 and BRCA2 mutations and breast cancer.

Discovery medicine 20111101

Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks?

Journal of clinical pathology 20111001

Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.

Molecular cancer therapeutics 20111001

PARP inhibitors--current status and the walk towards early breast cancer.

Breast (Edinburgh, Scotland) 20111001

Functional characterization of EMSY gene amplification in human cancers.

The Journal of pathology 20110901

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

The Lancet. Oncology 20110901

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.

Annals of oncology : official journal of the European Society for Medical Oncology 20110801

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology 20110701

Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110701

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

The Journal of clinical investigation 20110701

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

Nature medicine 20110701

PARP inhibitors: its role in treatment of cancer.

Chinese journal of cancer 20110701

The epistatic relationship between BRCA2 and the other RAD51 mediators in homologous recombination.

PLoS genetics 20110701

Epistatic relationships in the BRCA1-BRCA2 pathway.

PLoS genetics 20110701

Novel agents and future directions for refractory breast cancer.

Seminars in oncology 20110601

Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.

Nature reviews. Clinical oncology 20110501

5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2).

Journal of medicinal chemistry 20110414

MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor.

The Journal of biological chemistry 20110408

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.

British journal of cancer 20110301

Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method.

Angewandte Chemie (International ed. in English) 20110218

Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110215

Characteristics of triple-negative breast cancer.

Journal of cancer research and clinical oncology 20110201

'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis.

Current opinion in obstetrics & gynecology 20110201

Triple negative breast cancer: unmet medical needs.

Breast cancer research and treatment 20110201

Immunophenotypic predictive profiling of BRCA1-associated breast cancer.

Virchows Archiv : an international journal of pathology 20110101

Evaluation of the efficacy of radiation-modifying compounds using γH2AX as a molecular marker of DNA double-strand breaks.

Genome integrity 20110101

Breast cancer genome heterogeneity: a challenge to personalised medicine?

Breast cancer research : BCR 20110101

PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.

Acta clinica Belgica 20110101

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.

Journal of hematology & oncology 20110101

BRCA-deficient and triple negative breast cancers: is olaparib effective in both subtypes?

Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20110101

Concordant and opposite roles of DNA-PK and the 'facilitator of chromatin transcription' (FACT) in DNA repair, apoptosis and necrosis after cisplatin.

Molecular cancer 20110101

Targeted therapy in breast cancer: what's new?

Swiss medical weekly 20110101

Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.

Cancer management and research 20110101

Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.

BMC pharmacology 20110101

Rare variants in the ATM gene and risk of breast cancer.

Breast cancer research : BCR 20110101

Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.

PloS one 20110101

Drug therapy for hereditary cancers.

Hereditary cancer in clinical practice 20110101

Management options in triple-negative breast cancer.

Breast cancer : basic and clinical research 20110101

Genetic dissection of PARylation in the filamentous fungus Neurospora crassa.

Methods in molecular biology (Clifton, N.J.) 20110101

Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?

Breast cancer research : BCR 20110101

Platinum resistance in breast and ovarian cancer cell lines.

Journal of experimental & clinical cancer research : CR 20110101

MicroRNAs associated with metastatic prostate cancer.

PloS one 20110101

A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer.

BMC medical genetics 20110101

Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines.

BMC medical genomics 20110101

Rad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs.

PloS one 20110101

Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil.

PloS one 20110101

Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review.

International journal of surgical oncology 20110101

Triple-negative breast cancer: adjuvant therapeutic options.

Chemotherapy research and practice 20110101

Multidrug resistance in breast cancer: from in vitro models to clinical studies.

International journal of breast cancer 20110101

Therapeutic targeting of cancer stem cells.

Frontiers in oncology 20110101

BRCA mutations in the management of breast cancer: the state of the art.

Nature reviews. Clinical oncology 20101201

[PARP inhibitors to treat triple negative breast cancer].

Gan to kagaku ryoho. Cancer & chemotherapy 20101201

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.

Blood 20101125

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.

British journal of cancer 20101109

Targeting poly(ADP-ribose) polymerase activity for cancer therapy.

Cellular and molecular life sciences : CMLS 20101101

Molecule of the month. Olaparib.

Drug news & perspectives 20101101

Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination.

Nature structural & molecular biology 20101001

Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations.

Nature reviews. Clinical oncology 20101001

Role for the mammalian Swi5-Sfr1 complex in DNA strand break repair through homologous recombination.

PLoS genetics 20101001

PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.

Current opinion in oncology 20100901

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100901

Beyond PARP inhibitors: agents in pipelines target DNA repair mechanisms.

Journal of the National Cancer Institute 20100804

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

Lancet (London, England) 20100724

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

Lancet (London, England) 20100724

[Treatment with oral agents for breast cancer].

Gan to kagaku ryoho. Cancer & chemotherapy 20100701

Society for biomolecular sciences - 16th annual conference & exhibition - advancing the science of drug discovery.

IDrugs : the investigational drugs journal 20100601

Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.

Molecular cancer therapeutics 20100601

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100520

Multiple roles of BRIT1/MCPH1 in DNA damage response, DNA repair, and cancer suppression.

Yonsei medical journal 20100501

Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.

Cancer research 20100215

ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.

Molecular cancer therapeutics 20100201

A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research 20100101

The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer.

Journal of oncology 20100101

A current review of targeted therapeutics for ovarian cancer.

Journal of oncology 20100101

Targeted therapies in epithelial ovarian cancer.

Journal of oncology 20100101

Targeted therapy in ovarian cancer.

Journal of oncology 20100101

Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.

Breast cancer research : BCR 20100101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100101

Biology-driven cancer drug development: back to the future.

BMC biology 20100101

Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future.

Cancer journal (Sudbury, Mass.) 20100101

Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.

Breast cancer research : BCR 20100101

Does race affect outcomes in triple negative breast cancer?

Breast cancer : basic and clinical research 20100101

Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype.

BMC cancer 20100101

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer.

F1000 biology reports 20100101

Treatment options for patients with triple-negative breast cancer.

Journal of hematology & oncology 20100101

Present and future evolution of advanced breast cancer therapy.

Breast cancer research : BCR 20100101

Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone.

Breast cancer research : BCR 20100101

Triple-negative breast cancer.

Breast cancer research : BCR 20100101

Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers.

Breast cancer research : BCR 20100101

Are current development programs realising the full potential of new agents?

Breast cancer research : BCR 20100101

New developments in treatment of ovarian carcinoma: focus on trabectedin.

Cancer management and research 20100101

Preclinical mouse models for BRCA1-associated breast cancer.

British journal of cancer 20091117

Converting cancer mutations into therapeutic opportunities.

EMBO molecular medicine 20090901

Triple-negative breast cancer: novel therapies and new directions.

Maturitas 20090820

Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.

Cancer cell 20090804

Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90.

Molecular cancer therapeutics 20090801

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

The New England journal of medicine 20090709

Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.

Cancer research 20090501

Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.

Breast cancer research : BCR 20090101

BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?

Journal of ovarian research 20090101

Synthetic lethality: a framework for the development of wiser cancer therapeutics.

Genome medicine 20090101

PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?

Breast cancer research : BCR 20090101

Are current drug development programmes realising the full potential of new agents? The scenario.

Breast cancer research : BCR 20090101

Tailored targeted therapy for all: a realistic and worthwhile objective?

Breast cancer research : BCR 20090101

Recent advances in managing triple-negative breast cancers.

F1000 medicine reports 20090101

Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential.

International journal of radiation oncology, biology, physics 20081115

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.

Proceedings of the National Academy of Sciences of the United States of America 20081104

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

Journal of medicinal chemistry 20081023

A FlashPlate assay for the identification of PARP-1 inhibitors.

Journal of biomolecular screening 20030601